Akari Therapeutics was formed in September 2015 through the merger of Volution Immuno Pharmaceuticals, SA into Celsus Therapeutics, Plc., which then changed its name to Akari Therapeutics, Plc.
Akari Therapeutics is a company organized under the laws of England and Wales. Its ordinary shares are not traded but it has American Depository Shares (ADS) (each of which represents 100 ordinary shares) listed on the NASDAQ Capital Market under the ticker symbol AKTX.
An ADS is a U.S. dollar-denominated equity share of a non-U.S. company available for purchase on an American stock exchange. ADSs are issued by depository banks in the U.S. under agreement with the issuing company.
This ratio reflects the number of ordinary shares that correspond to 1 ADS. In the case of Akari Therapeutics, each ADS represents 100 ordinary shares.
If you hold ADSs in Akari Therapeutics please contact Akari Therapeutics’ depositary, Deutsche Bank. The office at which the ADSs are administered is located at 60 Wall Street, New York, NY 10005 or by telephone on (212) 250-2500. Please note, there may be a fee involved for replacing lost certificates.
For ADSs, you must send both your old and new addresses to Deutsche Bank, attention Beverly George, whose address is 60 Wall Street, New York, NY 10005.
Where shares are jointly held by more than one shareholder, each shareholder registered against the share in question must sign the request for an address change.
The Company’s SEC filing can be accessed on the Financial Information page of the Investor Relations portion of its website or can be accessed directly from the SEC’s website at www.sec.gov.
